乳腺癌治疗中的心脏保护

doi:10.3760/cma.j.cn371439-20200406-00103

摘要/Abstract

摘要：

乳腺癌患者患心血管疾病的概率更高,年龄大、射血分数低、冠状动脉疾病史、心脏危险因素、蒽环类药物联合曲妥珠单抗或放疗均会增加治疗后发生心脏事件的风险。利用超声心动图监测心脏状况,特别是对有高血压、糖尿病、高脂血症和肥胖等传统心脏危险因素或左心室射血分数正常基线偏低的患者可降低心脏危险事件。在蒽环类药物治疗期间肌钙蛋白升高和早期心肌变形,可能预示着射血分数的降低,但需要进一步的研究来证明常规筛选和早期治疗的临床益处。对于乳腺癌患者,戒烟、定期锻炼、健康饮食和保持健康体重等,可降低患心血管疾病的风险。

关键词: 乳腺肿瘤, 心力衰竭, 冠状动脉疾病, 高血压

Abstract:

Breast cancer patients have a higher risk of cardiovascular disease, older age, lower ejection fraction, history of coronary artery disease, cardiac risk factors, anthracycline combined with trastuzumab or radiotherapy will increase the risk of cardiac events after treatment. Echocardiographic monitoring the heart condition, especially for those patients with traditional heart risk factors such as hypertension, diabetes, hyperlipidemia and obesity or with low left ventricular ejection fraction at normal baseline, can reduce cardiac risk events. Elevated troponin and early myocardial deformation during anthracycline therapy may indicate a decrease in ejection fraction, but further studies are needed to prove the clinical benefits of routine screening and early treatment. For patients with breast cancer, smoking cessation,regular exercise, healthy diet and maintaining a healthy weight, etc., can reduce the risk of cardiovascular disease.

Key words: Breast neoplasms, Heart failure, Coronary artery disease, Hypertension

刘桂宾, 高杰, 马颖. 乳腺癌治疗中的心脏保护[J]. 国际肿瘤学杂志, 2020, 47(11): 695-699.

Liu Guibin, Gao Jie, Ma Ying. Heart protection in the treatment of breast cancer[J]. Journal of International Oncology, 2020, 47(11): 695-699.

参考文献 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(1):7-30. DOI: 10.3322/caac.21387. doi: 10.3322/caac.21387 pmid: 28055103
[2]	Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors[J]. Epidemiology, 2016,27(1):6-13. DOI: 10.1097/ede.0000000000000394. doi: 10.1097/EDE.0000000000000394 pmid: 26414938
[3]	Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association[J]. Circulation, 2017,135(10):e146-e603. DOI: 10.1161/CIR.0000000000000485.
[4]	Johnson CB, Davis MK, Law A, et al. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care of oncology patients[J]. Can J Cardiol, 2016,32(7):900-907. DOI: 10.1016/j.cjca.2016.04.008. doi: 10.1016/j.cjca.2016.04.008 pmid: 27343745
[5]	Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity[J]. Ann Pharmacother, 1994,28(9):1063-1072. DOI: 10.1177/106002809402800912. doi: 10.1177/106002809402800912 pmid: 7803884
[6]	Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)[J]. J Clin Oncol, 2017,35(23):2647-2655. DOI: 10.1200/JCO.2016.71.4147.
[7]	Narayan HK, Finkelman B, French B, et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up[J]. Circulation, 2017,135(15):1397-1412. DOI: 10.1161/CIRCULATIONAHA.116.023463. doi: 10.1161/CIRCULATIONAHA.116.023463 pmid: 28104715
[8]	Mackey JR, Pieńkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial[J]. Ann Oncol, 2016,27(6):1041-1047. DOI: 10.1093/annonc/mdw098. doi: 10.1093/annonc/mdw098 pmid: 26940688
[9]	Budd GT, Barlow WE, Moore HC, et al. SWOG S0221: a phase Ⅲ trial comparing chemotherapy schedules in highrisk early-stage breast cancer[J]. J Clin Oncol, 2015,33(1):58-64. DOI: 10.1200/JCO.2014.56.3296. doi: 10.1200/JCO.2014.56.3296 pmid: 25422488
[10]	Najafi S, Payandeh M, Sadeghi M. Phase Ⅱ study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer a randomised controlled clinical trial[J]. Contemp Oncol (Pozn), 2017,21(1):83-89. DOI: 10.5114/wo.2017.66661.
[11]	Del Mastro L, Levaggi A, Michelotti A, et al. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-Ⅲ randomized GONO-MIG5 trial[J]. Breast Cancer Res Treat, 2016,155(1):117-126. DOI: 10.1007/s10549-015-3655-1. doi: 10.1007/s10549-015-3655-1 pmid: 26661403
[12]	Gallucci G, Simeon V. Letter by Gallucci and Simeon Regarding Article, "Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy"[J]. Circulation, 2016,133(4):e362. DOI: 10.1161/CIRCULATIONAHA.115.017890. doi: 10.1161/CIRCULATIONAHA.115.017890 pmid: 26811279
[13]	Narayan HK, French B, Khan AM, et al. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction[J]. JACC Cardiovasc Imaging, 2016,9(10):1131-1141. DOI: 10.1016/j.jcmg.2015.11.024. pmid: 27085442
[14]	Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials[J]. Indian J Pharmacol, 2016,48(5):490-497. DOI: 10.4103/0253-7613.190719. doi: 10.4103/0253-7613.190719 pmid: 27721532
[15]	Tapio S. Pathology and biology of radiation-induced cardiac disease[J]. J Radiat Res, 2016,57(5):439-448. DOI: 10.1093/jrr/rrw064. doi: 10.1093/jrr/rrw064 pmid: 27422929
[16]	Saiki H, Petersen IA, Scott CG, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer[J]. Circulation, 2017,135(15):1388-1396. DOI: 10.1161/CIRCULATIONAHA.116.025434. doi: 10.1161/CIRCULATIONAHA.116.025434 pmid: 28132957
[17]	van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]. J Clin Oncol, 2017,35(11):1171-1178. DOI: 10.1200/JCO.2016.69.8480. doi: 10.1200/JCO.2016.69.8480 pmid: 28095159
[18]	Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2017,35(8):893-911. DOI: 10.1200/JCO.2016.70.5400. doi: 10.1200/JCO.2016.70.5400 pmid: 27918725
[19]	van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk[J]. JAMA Intern Med, 2015,175(6):1007-1017. DOI: 10.1001/jamainternmed.2015.1180. doi: 10.1001/jamainternmed.2015.1180 pmid: 25915855
[20]	Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children[J]. Pharmacogenomics, 2015,16(10):1065-1076. DOI: 10.2217/pgs.15.61. doi: 10.2217/pgs.15.61 pmid: 26230641
[21]	Schneider BP, Shen F, Gardner L, et al. Genome-wide association study for anthracycline-induced congestive heart failure[J]. Clin Cancer Res, 2017,23(1):43-51. DOI: 10.1158/1078-0432.CCR-16-0908. doi: 10.1158/1078-0432.CCR-16-0908 pmid: 27993963
[22]	Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracyclineinduced cardiotoxicity in childhood cancer[J]. Nat Genet, 2015,47(9):1079-1084. DOI: 10.1038/ng.3374. doi: 10.1038/ng.3374 pmid: 26237429
[23]	Burocchi S, Gori M, Cioffi G, et al. Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction[J]. Eur Heart J Cardiovasc Imaging, 2019,jez298. DOI: 10.1093/ehjci/jez298.
[24]	Hall TS, von Lueder TG, Zannad F, et al. Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction[J]. Int J Cardiol, 2018,272:260-266. DOI: 10.1016/j.ijcard.2018.07.137. doi: 10.1016/j.ijcard.2018.07.137 pmid: 30144995
[25]	Ozaydin M, Yucel H, Kocyigit S, et al. Nebivolol versus carvedilol or metoprolol in patients presenting with acute myocardial infarction complicated by left ventricular dysfunction[J]. Med Princ Pract, 2016,25(4):316-22. DOI: 10.1159/000446184. doi: 10.1159/000446184 pmid: 27164841
[26]	Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol, 2016,68(13):1476-1488. DOI: 10.1016/j.jacc.2016.05.011. pmid: 27216111
[27]	Krop IE, Modi S, Lorusso PM, et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer[J]. Breast Cancer Res, 2016,18(1):34. DOI: 10.1186/s13058-016-0691-7. doi: 10.1186/s13058-016-0691-7 pmid: 26979312
[28]	Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines[J]. Cardiol Young, 2015,25 Suppl 2: 107-116. DOI: 10.1017/S1047951115000906.
[29]	Biener M, Giannitsis E, Kuhner M, et al. Prognostic value of high-sensitivity cardiac troponin T compared to riskscores in stable cardiovascular disease[J]. Am J Med, 2017,130(5):572-582. DOI: 10.1016/j.amjmed.2016.11.028. doi: 10.1016/j.amjmed.2016.11.028 pmid: 28011313
[30]	Todorova VK, Makhoul I, Siegel ER, et al. Biomarkers for presymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients[J]. PLoS One, 2016,11(8):e0160224. DOI: 10.1371/journal.pone.0160224. doi: 10.1371/journal.pone.0160224 pmid: 27490685
[31]	Elghazawy H, Venkatesulu BP, Verma V, et al. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving anthracyclines ± trastuzumab: a meta-analysis of clinical studies[J]. Crit Rev Oncol Hematol, 2020,153:103006. DOI: 10.1016/j.critrevonc.2020.103006. doi: 10.1016/j.critrevonc.2020.103006 pmid: 32777728
[32]	Kollárová-Brázdová P, Jirkovská A, Karabanovich G, et al. Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase Ⅱβ interaction as a prerequisite for effective protection against anthracycline cardiotoxicity[J]. J Pharmacol Exp Ther, 2020,373(3):402-415. DOI: 10.1124/jpet.119.264580. pmid: 32253261
[33]	McGowan JV, Chung R, Maulik A, et al. Anthracycline chemothe-rapy and cardiotoxicity[J]. Cardiovasc Drugs Ther, 2017,31(1):63-75. DOI: 10.1007/s10557-016-6711-0. doi: 10.1007/s10557-016-6711-0 pmid: 28185035
[34]	Knapper JT, Ghasemzadeh N, Khayata M, et al. Time to change our focus: defining, promoting, and impacting cardiovascular population health[J]. J Am Coll Cardiol, 2015,66(8):960-971. DOI: 10.1016/j.jacc.2015.07.008. pmid: 26293767
[35]	Shin WK, Song S, Hwang E, et al. Development of a FFQ for breast cancer survivors in Korea[J]. Br J Nutr, 2016: 1-6. DOI: 10.1017/S000711451600372X. doi: 10.1017/S0007114520004961 pmid: 33298231